OncRef

Clinical Trial: NCT05707273

CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:City of Hope Medical Center
Information Provided By:City of Hope Medical Center
Last Update Posted:2026-10-08

Study Overview

Brief Summary

This phase I trial tests the safety, side effects, and best dose of autologous anti-CD19 CAR-expressing T lymphocytes (CD19-CAR T cells) in older adults with B-cell acute lymphoblastic leukemia. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of B-cell acute lymphoblastic leukemia.

Official Title

A Pilot Study of CD19-Specific Car T Cells as Consolidation for Older Adults With Acute Lymphoblastic Leukemia in First Remission

Conditions

B Acute Lymphoblastic Leukemia

Intervention / Treatment

  • Drug: Autologous Anti-CD19 CAR-expressing T Lymphocytes
  • Procedure: Biospecimen Collection
  • Procedure: Bone Marrow Aspiration and Biopsy
  • Drug: Cyclophosphamide
  • Drug: Fludarabine
  • Procedure: Leukapheresis
  • Other: Questionnaire Administration

Other Study ID Numbers

  • 22137
  • NCI-2022-10925
  • 22137
  • P30CA033572

Start Date (Actual)

2023-04-26

Primary Completion Date (Estimated)

2027-09-21

Study Completion Date (Estimated)

2027-09-21

Enrollment (Actual)

18

Study Type

Interventional

Phase

Phase 1